^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    NT-175

    i
    Other names: NT-175, NT175, NT 175
    Associations

    News

    Trials
    Company:
    AstraZeneca
    Drug class:
    TCR modulator, P53 expression modulator
    Related drugs:
    Associations

    News

    Trials
    3ms
    A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation (clinicaltrials.gov)
    P1, N=162, Recruiting, Neogene Therapeutics, Inc. | N=24 --> 162
    Enrollment change • Metastases
    |
    TP53 (Tumor protein P53) • HLA-A (Major Histocompatibility Complex, Class I, A)
    |
    cyclophosphamide • NT-175
    over1year
    A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation (clinicaltrials.gov)
    P1, N=24, Recruiting, Neogene Therapeutics, Inc. | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    TP53 (Tumor protein P53) • HLA-A (Major Histocompatibility Complex, Class I, A)
    |
    TP53 mutation • TP53 R175H • HLA-A*02:01 • HLA-A*02
    |
    cyclophosphamide • NT-175
    over1year
    A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation (clinicaltrials.gov)
    P1, N=24, Not yet recruiting, Neogene Therapeutics, Inc.
    New P1 trial • Metastases
    |
    TP53 (Tumor protein P53) • HLA-A (Major Histocompatibility Complex, Class I, A)
    |
    TP53 mutation • TP53 R175H • HLA-A*02:01 • HLA-A*02
    |
    cyclophosphamide • NT-175